Daniel Weintraub

Daniel Weintraub

Auto-generated profile, based on publicly available information

Daniel Weintraub

University of Pennsylvania

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
DWDaniel Weintraub
Daniel Weintraub
JKJuergen Koester
Juergen Koester
MPMarc N. Potenza
Marc N. Potenza
ASAndrew D. Siderowf
Andrew D. Siderowf
MSMark Stacy
Mark Stacy
ALAnthony E. Lang
Anthony E. Lang
Impulse control disorders (ICDs), including problem or pathological gambling, compulsive buying, compulsive sexual behavior, and binge or compulsive eating, have been reported in Parkinson disease (PD).1 Preliminary cross-sectional prevalence estimates of ICDs in this population range from 1.7% to 6.1% for gambling,2-5 2.0% to 4.0% for compulsive sexual behavior,2,4,6 and 0.4% to 3.0% for compulsive buying2,4,6; there has been no formal prevalence estimate for eating disorders in PD.

24 November 2009 in Neurology
Verified
Journal Article
Closed access
SHS. Hoops
S. Hoops
SNS. Nazem
S. Nazem
ASA. D. Siderowf
A. D. Siderowf
JDJ. E. Duda
J. E. Duda
SXS. X. Xie
S. X. Xie
DWD. Weintraub
D. Weintraub
Due to the high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson disease (PD), routine cognitive screening is important for the optimal management of patients with PD. The Montreal Cognitive Assessment (MoCA) is more sensitive than the commonly used Mini-Mental State Examination (MMSE) in detecting MCI and dementia in patients without PD, but its validity in PD has not been established. A representative sample of 132 patients with PD at 2 movement disorders centers was administered the MoCA, MMSE, and a neuropsychological battery with operationalized criteria for deficits. MCI and PD dementia (PDD) criteria were applied by an investigator blinded to the MoCA and MMSE results. The discriminant validity of the MoCA and MMSE as screening and diagnostic instruments was ascertained. Approximately one third of the sample met diagnostic criteria for a cognitive disorder (12.9% PDD and 17.4% MCI). Mean (SD) MoCA and MMSE scores were 25.0 (3.8) and 28.1 (2.0). The overall discriminant validity for detection of any cognitive disorder was similar for the MoCA and the MMSE (receiver operating characteristic area under the curve [95% confidence interval]): MoCA (0.79 [0.72, 0.87]) and MMSE (0.76 [0.67, 0.85]), but as a screening instrument the MoCA (optimal cutoff point = 26/27, 64% correctly diagnosed, lack of ceiling effect) was superior to the MMSE (optimal cutoff point = 29/30, 54% correctly diagnosed, presence of ceiling effect). The Montreal Cognitive Assessment, but not the Mini-Mental State Examination, has adequate psychometric properties as a screening instrument for the detection of mild cognitive impairment or dementia in Parkinson disease. However, a positive screen using either instrument requires additional assessment due to suboptimal specificity at the recommended screening cutoff point.

1 January 2022 in The Lancet Neurology
Verified
Journal Article
Closed access
DWDaniel Weintraub
Daniel Weintraub
DADag Aarsland
Dag Aarsland
KCKallol Ray Chaudhuri
Kallol Ray Chaudhuri
RDRoseanne D Dobkin
Roseanne D Dobkin
ALAlbert Fg Leentjens
Albert Fg Leentjens
ASAnette Schrag
Anette Schrag

5 May 2023 in Movement Disorders
Verified
Journal Article
Open access
SJStefanie T. Jost
Stefanie T. Jost
MKMarie‐Ann Kaldenbach
Marie‐Ann Kaldenbach
Angelo AntoniniAngelo Antonini
Angelo Antonini
PMPablo Martinez‐Martin
Pablo Martinez‐Martin
LTLars Timmermann
Lars Timmermann
TGthe International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
the International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.Objectives: To update LED conversion formulae based on a systematic review.Methods: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.Results: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.Conclusions: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

27 May 2011 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
DWDaniel Weintraub
Daniel Weintraub
DBDavid J. Burn
David J. Burn

1 December 2011 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
DWDaniel Weintraub
Daniel Weintraub
EMEugenia Mamikonyan
Eugenia Mamikonyan
KPKimberly Papay
Kimberly Papay
JSJudith A. Shea
Judith A. Shea
SXSharon X. Xie
Sharon X. Xie
ASAndrew Siderowf
Andrew Siderowf